lopinavir/ritonavir in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death or transfer to ICUdetailed results RECOVERY, 2020 1.09 [0.99; 1.20]
1.09 [0.99 ; 1.20 ] RECOVERY, 2020 1 0% 4,836 NA not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
RECOVERY, 2020 1.03 [0.91; 1.17]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
SOLIDARITY (lopi/rito), 2020 1.00 [0.79; 1.26]
0.98 [0.88 ; 1.09 ] Cao, 2020, RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, SOLIDARITY (lopi/rito), 2020 4 6% 8,655 moderate not evaluable deaths (time to event analysis only)detailed results REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
0.83 [0.65 ; 1.06 ] REMAP-CAP (lopinavir/ritonavir only), 2020 1 0% 645 NA not evaluable clinical deteriorationdetailed results ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
3.69 [0.37 ; 36.57 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
1.31 [0.94 ; 1.83 ] Cao, 2020 1 0% NA not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
1.23 [0.55 ; 2.76 ] Cao, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 2 84% 844 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
1.59 [0.84 ; 3.03 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
3.16 [0.62 ; 16.06 ] Cao, 2020 1 0% 199 NA not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
1.31 [0.94 ; 1.83 ] Cao, 2020 1 0% NA not evaluable hospital dischargedetailed results RECOVERY, 2020 0.98 [0.91; 1.05]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
0.92 [0.79 ; 1.08 ] RECOVERY, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 2 62% 5,685 moderate not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
0.48 [0.02 ; 11.28 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 25 NA not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
0.10 [0.00 ; 2.09 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 25 NA not evaluable viral clearance detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
1.28 [0.19 ; 8.76 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable viral clearance by day 14detailed results ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
1.28 [0.19 ; 8.76 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable viral clearance by day 7detailed results ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
0.30 [0.05 ; 1.91 ] ELACOI (lopinavir/ritonavir), 2020 1 0% 28 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
0.88 [0.30 ; 2.58 ] Cao, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020 2 77% 811 moderate not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 03:51 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 509
- roots T: 290